Literature DB >> 11145392

Gentamicin release from polymethylmethacrylate bone cements and Staphylococcus aureus biofilm formation.

H van de Belt1, D Neut, W Schenk, J R van Horn, H C van der Mei, H J Busscher.   

Abstract

We measured the formation of a Staphylococcus aureus biofilm in vitro on unloaded and gentamicin-loaded bone cements (CMW3 and Palacos R) and related the formation to antibiotic release rates. All experiments were done in triplicate. Microbial growth on gentamicin-loaded cements occurred despite the release of antibiotic. Biofilm formation on gentamicin loaded CMW3 bone cement was one fourth to one fifth less than on the unloaded bone cement, while biofilm formation on Palacos R bone cement was not significantly affected by antibiotic loading. More gentamicin was released from CMW3 (79 mg) than from Palacos R (70 mg), but the percentage gentamicin released after one week relative to the total amount incorporated was significantly lower for CMW3 (4.7%) than for Palacos R (8.4%). After one day, subinhibitory concentrations of antibiotics were eluted from the cements. We concluded that antibiotic-loaded bone cement does not necessarily inhibit the formation of an infectious biofilm in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145392     DOI: 10.1080/000164700317362280

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  42 in total

1.  Does adding antibiotics to cement reduce the need for early revision in total knee arthroplasty?

Authors:  Eric Bohm; Naisu Zhu; Jing Gu; Nicole de Guia; Cassandra Linton; Tammy Anderson; David Paton; Michael Dunbar
Journal:  Clin Orthop Relat Res       Date:  2014-01       Impact factor: 4.176

2.  The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts. An in vitro study.

Authors:  Aasis Unnanuntana; Lindsay Bonsignore; Mark E Shirtliff; Edward M Greenfield
Journal:  J Bone Joint Surg Am       Date:  2009-11       Impact factor: 5.284

3.  Reinfected revised TKA resolves with an aggressive protocol and antibiotic infusion.

Authors:  Leo A Whiteside; Tariq A Nayfeh; Renee LaZear; Marcel E Roy
Journal:  Clin Orthop Relat Res       Date:  2012-01       Impact factor: 4.176

Review 4.  Antimicrobial technology in orthopedic and spinal implants.

Authors:  Adam Em Eltorai; Jack Haglin; Sudheesha Perera; Bielinsky A Brea; Roy Ruttiman; Dioscaris R Garcia; Christopher T Born; Alan H Daniels
Journal:  World J Orthop       Date:  2016-06-18

5.  Liquid dextran does not increase the elution rate of different antibiotics from bone cement.

Authors:  K E Roth; B Krause; E Siegel; G Maier; C Schoellner; P M Rommens
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-01-11

6.  Effect of pulsed ultrasound in combination with gentamicin on bacterial viability in biofilms on bone cements in vivo.

Authors:  G T Ensing; B L Roeder; J L Nelson; J R van Horn; H C van der Mei; H J Busscher; W G Pitt
Journal:  J Appl Microbiol       Date:  2005       Impact factor: 3.772

Review 7.  Microbial resistance related to antibiotic-loaded bone cement: a historical review.

Authors:  Lucy C Walker; Paul Baker; Richard Holleyman; David Deehan
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-09-12       Impact factor: 4.342

8.  Treatment of osteomyelitis in rats by injection of degradable polymer releasing gentamicin.

Authors:  Yaron S Brin; Jacob Golenser; Boaz Mizrahi; Guy Maoz; Abraham J Domb; Shyamal Peddada; Shmuel Tuvia; Abraham Nyska; Meir Nyska
Journal:  J Control Release       Date:  2008-07-20       Impact factor: 9.776

Review 9.  Rationale for one stage exchange of infected hip replacement using uncemented implants and antibiotic impregnated bone graft.

Authors:  Heinz Winkler
Journal:  Int J Med Sci       Date:  2009-09-04       Impact factor: 3.738

Review 10.  Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach.

Authors:  Esa Jämsen; Ioannis Stogiannidis; Antti Malmivaara; Jorma Pajamäki; Timo Puolakka; Yrjö T Konttinen
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.